iBio Inc (NASDAQ: IBIO) on Monday, soared 14.25% from the previous trading day, before settling in for the closing price of $0.92. Within the past 52 weeks, IBIO’s price has moved between $0.64 and $6.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -18.92% annually for the last half of the decade. The company achieved an average annual earnings per share of 60.55%. With a float of $9.31 million, this company’s outstanding shares have now reached $9.87 million.
In an organization with 19 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 209.87%, operating margin of -4134.67%, and the pretax margin is -3795.73%.
iBio Inc (IBIO) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of iBio Inc is 5.67%, while institutional ownership is 26.65%. The most recent insider transaction that took place on Jan 10 ’25, was worth 25,000. In this transaction Chief Financial Officer of this company bought 9,191 shares at a rate of $2.72, taking the stock ownership to the 11,139 shares. Before that another transaction happened on Jan 10 ’25, when Company’s insider bought 9,191 for $2.72, making the entire transaction worth $25,000. This insider now owns 18,316 shares in total.
iBio Inc (IBIO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 45.01% during the next five years compared to 57.55% growth over the previous five years of trading.
iBio Inc (NASDAQ: IBIO) Trading Performance Indicators
iBio Inc (IBIO) is currently performing well based on its current performance indicators. A quick ratio of 1.76 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.70, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.38 in one year’s time.
Technical Analysis of iBio Inc (IBIO)
Let’s dig in a bit further. During the last 5-days, its volume was 2.97 million. That was better than the volume of 0.72 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 51.10%. Additionally, its Average True Range was 0.33.
During the past 100 days, iBio Inc’s (IBIO) raw stochastic average was set at 6.62%, which indicates a significant decrease from 43.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 169.32% in the past 14 days, which was higher than the 164.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.5417, while its 200-day Moving Average is $2.7051. However, in the short run, iBio Inc’s stock first resistance to watch stands at $1.2000. Second resistance stands at $1.3499. The third major resistance level sits at $1.4799. If the price goes on to break the first support level at $0.9201, it is likely to go to the next support level at $0.7901. The third support level lies at $0.6402 if the price breaches the second support level.
iBio Inc (NASDAQ: IBIO) Key Stats
Market capitalization of the company is 10.37 million based on 9,875K outstanding shares. Right now, sales total 230 K and income totals -24,910 K. The company made 200 K in profit during its latest quarter, and -4,360 K in sales during its previous quarter.
